There's still only one biosimilar on the US market, but the third quarter earnings calls this year may have marked the point where updates about them became routine, with firms discussing the products just as they would any pipeline project or potential competitor.
Novartis AG, for one, confirmed during its third quarter earnings call that its application for a biosimilar version of...






